Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Topics

Select Topic

Showing 1,267 results.

Thumbnail for Efficacy and Safety of Asciminib as Second-Line or Later Therapy in Chronic-Phase Chronic Myeloid Leukemia: An Updated Systematic Review and Meta-Analysis

CML - 426

Efficacy and Safety of Asciminib as Second-Line or Later Therapy in Chronic-Phase Chronic Myeloid Leukemia: An Updated Systematic Review and Meta-Analysis

Shivam Rainchwar

Poster Presenter: Shivam Rainchwar

Thumbnail for Updated efficacy and safety data from an ongoing phase 1a/b trial of the Bruton's tyrosine kinase (BTK) degrader bexobrutideg (NX-5948) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) across lines of therapy

CLL - 427

Updated efficacy and safety data from an ongoing phase 1a/b trial of the Bruton's tyrosine kinase (BTK) degrader bexobrutideg (NX-5948) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) across lines of therapy

Zulfa Omer

Poster Presenter: Zulfa Omer

Previous 1...30 31 32 33 34 35 36...141 Next

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

Thumbnail for Does triple trisomy (+4, +10, +17) remain prognostically significant factor in pediatric high hyperdiploid acute lymphoblastic leukemia (HD-ALL)?

ALL - 428

Does triple trisomy (+4, +10, +17) remain prognostically significant factor in pediatric high hyperdiploid acute lymphoblastic leukemia (HD-ALL)?

Elza Lomaia

Poster Presenter: Elza Lomaia

Thumbnail for Daybreak CLL-201: A Study of Bexobrutideg (NX-5948), a Bruton Tyrosine Kinase (BTK) Degrader, in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Treated With a Covalent BTK Inhibitor, a Noncovalent BTK Inhibitor, and a BCL2 Inhibitor

CLL - 429

Daybreak CLL-201: A Study of Bexobrutideg (NX-5948), a Bruton Tyrosine Kinase (BTK) Degrader, in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Treated With a Covalent BTK Inhibitor, a Noncovalent BTK Inhibitor, and a BCL2 Inhibitor

Michael Tees

Poster Presenter: Michael Tees

Thumbnail for Extracellular Vesicles in Autologous Serum Eye Drops Display Distinct Immunoregulatory Signatures in Ocular Chronic Graft-Versus-Host Disease

CT - 430

Extracellular Vesicles in Autologous Serum Eye Drops Display Distinct Immunoregulatory Signatures in Ocular Chronic Graft-Versus-Host Disease

Rachel Crossland

Poster Presenter: Rachel Crossland

$Thumbnail for DAYBreak CLL-306: A Phase 3 Randomized Open-Label Trial of the Novel Bruton Tyrosine Kinase Degrader Bexobrutideg (NX-5948) vs Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma$

CLL - 432

DAYBreak CLL-306: A Phase 3 Randomized Open-Label Trial of the Novel Bruton Tyrosine Kinase Degrader Bexobrutideg (NX-5948) vs Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Megan Wang

Poster Presenter: Megan Wang

Thumbnail for Effect of Ianalumab Plus Eltrombopag on Patient-Reported Outcomes in Primary Immune Thrombocytopenia: Results from the VAYHIT2 Phase 3 Trial

MDS - 435

Effect of Ianalumab Plus Eltrombopag on Patient-Reported Outcomes in Primary Immune Thrombocytopenia: Results from the VAYHIT2 Phase 3 Trial

Mary Lisha Paul

Poster Presenter: Mary Lisha Paul

Thumbnail for Efficacy and Safety of Pirtobrutinib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Systematic Review and Meta-Analysis

CLL - 437

Efficacy and Safety of Pirtobrutinib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Systematic Review and Meta-Analysis

Madho Mal

Poster Presenter: Madho Mal

$Thumbnail for Mosunetuzumab Plus Polatuzumab Vedotin (Mosun-Pola) vs Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) in Patients With Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Updated Efficacy and Safety From the Phase 3 SUNMO Study Including Second-Line (2L) vs Third-Line Plus (3L+) Patient Subgroups$

ABCL - 438

Mosunetuzumab Plus Polatuzumab Vedotin (Mosun-Pola) vs Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) in Patients With Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Updated Efficacy and Safety From the Phase 3 SUNMO Study Including Second-Line (2L) vs Third-Line Plus (3L+) Patient Subgroups

Jason Westin

Poster Presenter: Jason Westin

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors